Dataset from Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00012387
下载链接
链接失效反馈官方服务：
资源简介：
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
创建时间：
2025-12-16
